Union européenne -
français -
EMA (European Medicines Agency)
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - agents antinéoplasiques - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Union européenne -
français -
EMA (European Medicines Agency)
orserdu
stemline therapeutics b.v. - elacestrant - néoplasmes du sein - la thérapie endocrinienne - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
France -
français -
ANSES (Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail)
sergotonine
boehringer ingelheim animal health france - ergométrine (sous forme de maléate), sérotonine (sous forme de sulfate de créatinine monohydraté) - solution injectable - produits gynécologiques, alcaloïde de l'ergot de seigle en association - bovins, caprins, equins, ovins, porcins
Union européenne -
français -
EMA (European Medicines Agency)
zoledronic acid teva pharma
teva b.v. - acide zolédronique - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - médicaments pour le traitement des maladies osseuses - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. le traitement de la maladie de paget de l'os chez les adultes.